disease (PD), diabetes (DM), number of vascular comorbidities, BMI >30 and patient age.
INTRODUCTION AND OBJECTIVES:
The inflatable penile prosthesis (IPP) is the gold standard for the treatment of erectile dysfunction refractory to medical management. Loss of penile length after IPP implantation is a concern for many patients with ED who choose surgical treatment. Evidence of preservation of penile length in the postoperative setting would enhance functional outcomes and could remove a potential barrier to intervention. The purpose of the study was to evaluate the effectiveness of the Coloplast (Minneapolis, MN) Titanâ cylinders in maintaining penile length post-IPP implantation in patients treated for ED.
METHODS: A single-armed, multi-center, multi-surgeon, prospective study was conducted with 117 patients. These surgeries were performed via both an infrapubic and a penoscrotal approach. Each penis was measured via flaccid stretch using a Furlow device from the dorsal penile base (pressed against pubic bone) to the tip of the glans. The corpora were engorged intra-operatively with an artificial saline erection (ASE). Corporal cylinders were selected based on measured corporal length without upsizing. Erect measurements were taken during both the ASE and after inflating the implanted device, in both instances from the same positions as preoperatively. Statistical difference and correlation coefficients between the preoperative penile stretch test (PST), intra-operative artificial saline erection (ASE) and erect prosthetic length (EPL) were calculated. RESULTS: The mean patient age was 65.42 +/-7.8 years. The average preoperative penile stretch was 15.03 cm, artificial erection 14.76 cm, and average erect prosthetic length was 15.28 cm. The differences between all three of these measurements reached statistical significance based on the 95% confidence intervals. On average the EPL was 0.25 cm greater than the PST. CONCLUSIONS: Preoperative penile length was preserved and exceeded in our series, which challenges the conventional wisdom that loss of penile length is a foregone conclusion after IPP placement. This suggests that chronic hypoxia due to lack of neurovascular inputs, or scarring from Peyronie's disease, radiation, previous surgery, or medical conditions, are the main culprits of loss of penile length as males age. We recommend early intervention in patients that fail conservative therapy for erectile dysfunction to preserve maximal length.
Source of Funding: none

MP25-04 COST-EFFECTIVENESS OF IPP VERSUS INJECTION TREATMENT IN PATIENTS WHO FAIL ORAL MEDICATION
Nancy Wang*, Remy Lamberts, Stanford, CA; Catherine Harris, San Jose, CA INTRODUCTION AND OBJECTIVES: Erectile dysfunction is reported in up to 50% of men 40 years old and older, with the real number likely higher due to negative reporting bias. Although first line medication options have increased in the last few decades, approximately 30-35% of men still fail oral medications. Furthermore, healthy men are reporting average sexually active life expectancies up to 70 years old. We analyzed the cost-effectiveness of intracorporeal injection (ICI) therapy versus inflatable penile prostheses (IPP) management for patients who fail Viagra therapy.
METHODS: We performed a cost effective analysis using published complication and efficacy data, Medicare reimbursement costs, and commercial cost data. We compared the cost of IPP treatment including rate of infection, mechanical failure and re-operation with ICI treatment over a 15-year time-span, which is the average life of an IPP.
RESULTS: Compared with ICI, IPP was more cost-effective although the overall cost (ICI $15,570 vs IPP $13,571) and health utility (ICI 0.93 vs IPP 0.92) was comparable in both groups. Oneway sensitivity analysis showed that injections became cheaper, while maintaining similar efficacy at a cost less than $17.22 per injection. Similarly, when the frequency of monthly sexual intercourse fell below 3.5 times per month, ICI became the less costly option.
CONCLUSIONS: The average sexual lifespan of a healthy man in his 50s is estimated at 15 years and increasing. The price of injections and the rate of monthly injections were significant factors driving costs. Our study shows that IPP is the less costly approach for men overall. However, for men who successfully respond to less costly injection formulations and are happy with a lower frequency of monthly sexual intercourse, ICI may be a less costly option with similar successful outcomes. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e311
